Rhythm Pharmaceuticals, Inc. (RYTM)
RYTM Stock Price Chart
Explore Rhythm Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RYTM price movements and trends.
RYTM Company Profile
Discover essential business fundamentals and corporate details for Rhythm Pharmaceuticals, Inc. (RYTM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Oct 2017
Employees
283.00
Website
https://www.rhythmtx.comCEO
David Meeker
Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
RYTM Financial Timeline
Browse a chronological timeline of Rhythm Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.82, while revenue estimate is $67.58m.
Earnings released on 5 May 2026
EPS came in at -$0.83 surpassing the estimated -$0.86 by +3.49%, while revenue for the quarter reached $60.11m , beating expectations by +7.77%.
Earnings released on 26 Feb 2026
EPS came in at -$0.73 surpassing the estimated -$0.79 by +7.59%, while revenue for the quarter reached $57.25m , beating expectations by +1.86%.
Earnings released on 4 Nov 2025
EPS came in at -$0.82 falling short of the estimated -$0.72 by -13.89%, while revenue for the quarter reached $51.30m , missing expectations by -8.36%.
Earnings released on 5 Aug 2025
EPS came in at -$0.75 falling short of the estimated -$0.66 by -13.64%, while revenue for the quarter reached $48.50m , missing expectations by -5.51%.
Earnings released on 7 May 2025
EPS came in at -$0.81 falling short of the estimated -$0.69 by -17.39%, while revenue for the quarter reached $32.70m , missing expectations by -24.44%.
Earnings released on 26 Feb 2025
EPS came in at -$0.72 falling short of the estimated -$0.69 by -4.35%, while revenue for the quarter reached $41.83m , beating expectations by +8.69%.
Earnings released on 5 Nov 2024
EPS came in at -$0.73 surpassing the estimated -$0.80 by +8.75%, while revenue for the quarter reached $33.25m , missing expectations by -7.45%.
Earnings released on 6 Aug 2024
EPS came in at -$0.55 surpassing the estimated -$0.70 by +21.43%, while revenue for the quarter reached $29.08m , beating expectations by +1.00%.
Earnings released on 7 May 2024
EPS came in at -$2.35 falling short of the estimated -$2.34 by -0.43%, while revenue for the quarter reached $25.97m , missing expectations by -9.81%.
Earnings released on 22 Feb 2024
EPS came in at -$0.70 matching the estimated -$0.70, while revenue for the quarter reached $24.23m , missing expectations by -4.52%.
Earnings released on 7 Nov 2023
EPS came in at -$0.76 matching the estimated -$0.76, while revenue for the quarter reached $22.50m , missing expectations by -14.60%.
Earnings released on 1 Aug 2023
EPS came in at -$0.82 falling short of the estimated -$0.80 by -2.50%, while revenue for the quarter reached $19.22m , missing expectations by -16.28%.
Earnings released on 2 May 2023
EPS came in at -$0.92 falling short of the estimated -$0.71 by -29.58%, while revenue for the quarter reached $11.47m , missing expectations by -5.37%.
Earnings released on 1 Mar 2023
EPS came in at -$0.75 surpassing the estimated -$0.82 by +8.54%, while revenue for the quarter reached $8.79m , beating expectations by +21.77%.
Earnings released on 8 Nov 2022
EPS came in at -$0.79 surpassing the estimated -$1.01 by +21.78%, while revenue for the quarter reached $4.28m , missing expectations by -10.02%.
Earnings released on 2 Aug 2022
EPS came in at -$0.89 falling short of the estimated -$0.79 by -12.66%, while revenue for the quarter reached $9.07m , beating expectations by +253.38%.
Earnings released on 3 May 2022
EPS came in at -$1.05 falling short of the estimated -$0.98 by -7.14%, while revenue for the quarter reached $1.50m , missing expectations by -34.87%.
Earnings released on 1 Mar 2022
EPS came in at -$0.85 surpassing the estimated -$1.00 by +15.00%, while revenue for the quarter reached $1.82m , beating expectations by +6.75%.
Earnings released on 2 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.84 by +16.67%, while revenue for the quarter reached $1.03m , beating expectations by +9.36%.
Earnings released on 3 Aug 2021
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%, while revenue for the quarter reached $274.00k , meeting expectations.
RYTM Stock Performance
Access detailed RYTM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
